Plus Therapeutics Inc
Research Plus Therapeutics Inc (PSTV) on Bullrun: market cap USD 26.34M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPSTV
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 26.34M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 6.95M
- Free cash flow-USD 21.72M
Valuation Snapshot
latest market cap is USD 26.34M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 5.21M | -USD 22.39M | -USD 20.84M | n/a | -0.29 | USD 4.26M | USD 821.00K | USD 4.00M |
| FY2024 | USD 5.82M | -USD 12.98M | -USD 10.70M | n/a | -2.34 | USD 76.00K | USD 3.37M | -USD 8.95M |
| FY2023 | USD 4.91M | -USD 13.32M | -USD 13.01M | n/a | -4.24 | USD 8.55M | USD 3.98M | -USD 1.35M |
| FY2022 | n/a | -USD 20.28M | n/a | n/a | -11.58 | USD 18.12M | USD 5.39M | USD 6.45M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-07 | USD 26.34M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 70.72M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 6.78M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 7.91M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 10.75M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 16.30M | n/a | n/a | n/a |
About Plus Therapeutics Inc
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Plus Therapeutics Inc's market cap?
Plus Therapeutics Inc's market capitalization is USD 26.34M.
What does Plus Therapeutics Inc do?
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection.